GSK3B and osteosarcoma: The TOP/FOP flash assay showed a significant increase in T-cell factor-dependent promoter activity in osteosarcoma cells following treatment with GSK-3β inhibitors (Figure 5C), reflecting an increase in the co-transcriptional activity of β-catenin.